Suzhou, China

Shanghai Yu

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Hepagene Therapeutics (Hk) Limited. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shanghai Yu. Retrieved from https://idiyas.com/inventor/shanghai-yu-jnndjsxm

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Shanghai Yu - Innovator in Pharmaceutical Chemistry

Introduction

Shanghai Yu is a notable inventor based in Suzhou, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on THR-β receptor agonists. His research focuses on improving the efficacy and selectivity of pharmaceutical compounds.

Latest Patents

Shanghai Yu holds a patent for a compound titled "Heterocyclic THR-β receptor agonist compound and preparation method and use therefor." This chemical compound, represented in formula (I), includes an isomer or a pharmaceutically acceptable salt. The compound enhances THR-β agonistic activity while also improving selectivity for THR-α, thereby enhancing pharmaceutical quality. He has 1 patent to his name.

Career Highlights

Throughout his career, Shanghai Yu has worked with prominent companies in the pharmaceutical industry. He has been associated with Hepagene Therapeutics (HK) Limited and Suzhou Vincentage Pharma Co., Ltd. His work in these organizations has contributed to advancements in drug development and therapeutic solutions.

Collaborations

Shanghai Yu has collaborated with various professionals in his field, including his coworker Ben Li. Their joint efforts have furthered research and innovation in pharmaceutical applications.

Conclusion

Shanghai Yu is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in drug development. His innovative approach to THR-β receptor agonists showcases his commitment to improving pharmaceutical quality and efficacy.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…